Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-factor IX monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- Beijing Children's Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Anti-factor IX monoclonal antibodies are a class of therapeutic biologics designed to bind to and inhibit the activity of coagulation factor IX (FIX) or its activated form (FIXa). By targeting the intrinsic pathway of the blood coagulation cascade, these antibodies serve as anticoagulants for the prevention and treatment of thromboembolic diseases. A specific research initiative at Beijing Children’s Hospital, Capital Medical University, involves identifying and characterizing natural human anti-FIX antibodies derived from pediatric hemophilia B patients who have developed inhibitors. This exploratory study utilizes single B-cell sequencing to discover antibodies with potent in vitro anticoagulant activity and evaluates their antithrombotic effects and safety profiles in humanized mouse models. The goal is to develop novel antithrombotic therapies that provide effective anticoagulation with a reduced risk of bleeding complications compared to traditional anticoagulants.
- Other names
- anti-factor IX monoclonal antibodyanti-FIX antibodyFactor IX inhibitor antibody
02
Targets
F9 (Coagulation Factor IX)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on anti-factor IX monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-factor IX monoclonal antibody.